Por favor, use este identificador para citar o enlazar este ítem: 10.1111/jvp.12442

Registro completo de metadatos
Campo DCValorLengua/Idioma
dc.contributor.authorEscudero, Ana I.-
dc.contributor.authorMarín, Pedro-
dc.contributor.authorCárceles Rodríguez, Carlos-
dc.contributor.authorEscudero, Elisa-
dc.contributor.otherFacultades, Departamentos, Servicios y Escuelas::Departamentos de la UMU::Farmacologíaes
dc.date.accessioned2021-03-24T16:20:53Z-
dc.date.available2021-03-24T16:20:53Z-
dc.date.issued2018-02-
dc.identifier.urihttp://hdl.handle.net/10201/105601-
dc.description.abstractThe pharmacokinetic of deflazacort after intravenous and oral administration and the effect of erythromycin on the disposition of deflazacort in rabbits were investigated. A parallel study was carried out in twelve rabbits. The plasma concentration-time profiles of deflazacort were determined after intravenous and oral administration of single dosages of 5 mg/kg in the presence and absence (baseline) of multiple dose erythromycin regimens. Plasma levels of 21-desacetyldeflazacort were determined by HPLC. Plasma concentration-time curves were analysed by compartmental pharmacokinetic and non-compartmental methods. The t½z values following intravenous and oral administration were 3.67 and 4.96 h, respectively. The apparent volume of distribution at steady state (Vss) was 4.08 ± 0.31 L/kg, this value indicates that deflazacort is widely distributed into the extravascular tissues. Moreover, bioavailability after oral administration of deflazacort (F = 87.48 %) was high. Pharmacokinetic analysis after both routes of administration revealed a significant reduction in total body clearance, a significant increase in mean residence time, half-life and plasma concentrations of the steroid in the presence of multiple dose erythromycin. The results indicated the influence of the erythromycin on deflazacort disposition, which is consistent with a pharmacokinetic-type interaction in the elimination of the drug from the body. Moreover this interaction should be considered to avoid adverse effects when using both drugs concomitantly.es
dc.formatapplication/pdfes
dc.format.extent18es
dc.languageenges
dc.relationSin financiación externa a la Universidades
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectDeflazacort; erythromycin; interaction; pharmacokinetics; rabbits.es
dc.titlePHARMACOKINETICS OF DEFLAZACORT IN RABBITS AFTER INTRAVENOUS AND ORAL ADMINISTRATION AND ITS INTERACTION WITH ERYTHROMYCINes
dc.title.alternativeERYTHROMYCIN EFFECT ON DEFLAZACORT DISPOSITIONes
dc.typeinfo:eu-repo/semantics/articlees
dc.identifier.doi10.1111/jvp.12442-
Aparece en las colecciones:Artículos: Farmacología

Ficheros en este ítem:
Fichero Descripción TamañoFormato 
Deflazacort.pdfDeflazacort erythromycin interaction233,85 kBAdobe PDFVista previa
Visualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons